Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Zuranolone Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model

NCT03284931
View directory record Official record
Conditions
Healthy
Interventions
SAGE-217 high dose, Placebo, SAGE-217 low dose
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 4, 2026, 4:09 PM EDT
Recruiting Phase 2 Interventional

Allopregnanolone (Zuranolone) in Post-stroke Depression

NCT06759558
View directory record Official record
Conditions
Post Stroke Depression
Interventions
Zuranolone
Drug
Lead sponsor
Duke University
Other
Eligibility
21 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 4, 2026, 4:09 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder

NCT04007367
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
46
States / cities
Bentonville, Arkansas • Bellflower, California • Garden Grove, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 4, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)

NCT04442490
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
39
States / cities
Rogers, Arkansas • Bellflower, California • Garden Grove, California + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 4, 2026, 4:09 PM EDT
Recruiting No phase listed Observational

A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy

NCT07047820
View directory record Official record
Conditions
Depression, Postpartum
Interventions
Zuranolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Woonsocket, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 4, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease

NCT03000569
View directory record Official record
Conditions
Parkinson Disease
Interventions
SAGE-217, Levodopa, Antiparkinsonian Agent(s)
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Panorama City, California • Jacksonville, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 4, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Results available

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

NCT04476030
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
SAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
51
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 4, 2026, 4:09 PM EDT
Recruiting No phase listed Observational

A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone

NCT07398469
View directory record Official record
Conditions
Postpartum Depression
Interventions
Zuranolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 4, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)

NCT03864614
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SAGE-217
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
52
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 4, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)

NCT04442503
View directory record Official record
Conditions
Depression, Postpartum
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
68
States / cities
Scottsdale, Arizona • Bentonville, Arkansas • Anaheim, California + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 4, 2026, 4:09 PM EDT
Completed Phase 1 Interventional

Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)

NCT05655507
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Zuranolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
12 Years to 17 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Atlanta, Georgia • Decatur, Georgia • Flowood, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 4, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode

NCT03692910
View directory record Official record
Conditions
Bipolar Disorder I, Bipolar Disorder II, Major Depressive Episode
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
11
States / cities
Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 4, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Essential Tremor

NCT02978781
View directory record Official record
Conditions
Essential Tremor
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
26
States / cities
Anniston, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 4, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder

NCT03000530
View directory record Official record
Conditions
Major Depression
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Garden Grove, California • Orlando, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 4, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

NCT02978326
View directory record Official record
Conditions
Postpartum Depression
Interventions
SAGE-217 15/20 mg Oral Solution, Placebo, SAGE 217 30 mg Capsules
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
27
States / cities
Little Rock, Arkansas • Beverly Hills, California • Oceanside, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Sep 4, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder

NCT03672175
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
53
States / cities
Rogers, Arkansas • Bellflower, California • Garden Grove, California + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 4, 2026, 4:09 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia

NCT03771664
View directory record Official record
Conditions
Major Depressive Disorder, Insomnia
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
28
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Garden Grove, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 4, 2026, 4:09 PM EDT